SCHEMBL11233455

SCHEMBL11233455

COC(=O)CCOc1ccc(OC)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.66
MTNR1A P48039 1/20 0.59
MTNR1B P49286 1/20 0.59
ALDH1A1 P00352 6/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
KMT2A Q03164 2/20 0.58
MEN1 O00255 1/20 0.58
NPC1 O15118 1/20 0.58
CYP1A2 P05177 1/20 0.58
CYP3A4 P08684 1/20 0.58
CYP2D6 P10635 1/20 0.58
CYP2C9 P11712 1/20 0.58
CYP2C19 P33261 1/20 0.58
RAB9A P51151 1/20 0.58
HTT P42858 2/20 0.57
RECQL P46063 1/20 0.57
TSHR P16473 1/20 0.56
TP53 P04637 1/20 0.56
HPGD P15428 2/20 0.55
LMNA P02545 2/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14566050 0.87 MAPT (0.56) MAPTMTNR1AMTNR1BALDH1A1SMN1; SMN2
SCHEMBL10738896 0.87 L3MBTL1 (0.68) MAPTALDH1A1KMT2ANPC1RAB9A
SCHEMBL1932026 0.87 MAPT (0.53) MAPTALDH1A1KMT2AHTTLMNA
SCHEMBL7697086 0.87 MAPT (0.53) MAPTMTNR1AMTNR1BALDH1A1SMN1; SMN2
SCHEMBL4677996 0.85 MAPT (0.52) MAPTMTNR1AMTNR1BALDH1A1SMN1; SMN2
SCHEMBL21991488 0.85 PTGS2 (0.58) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL21991820 0.85 LTA4H (0.55) MAPTALDH1A1SMN1; SMN2KMT2AHTT
SCHEMBL20898309 0.85 MAPT (0.60) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL435675 0.85 MAPT (0.52) MAPTALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL1811389 0.85 RAB9A (0.59) MAPTMTNR1AMTNR1BALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-57072938-A None JP disclosed
US-20220409566-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-12-29 US disclosed
US-20220142961-A1 CCL5 Inhibitors LAPKO INC, dba AFECTA PHARMACEUTICALS 2022-05-12 US disclosed
US-11318111-B2 CCL5 inhibitors LAPKO INC (US) 2022-05-03 US disclosed
US-20210196665-A1 CCL5 Inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-07-01 US disclosed
US-10940132-B2 CCL5 inhibitors AFECTA PHARMACEUTICALS, INC. (US) 2021-03-09 US disclosed
US-20200138766-A1 CCL5 INHIBITORS LAPKO INC. DBA AFECTA PHARMACEUTICALS 2020-05-07 US disclosed
JP-S5772938-A NEMATOCIDE MUNAKATA KATSURA 1982-05-07 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220142961-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885
US-20200138766-A1 CCL5 INHIBITORS CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885
US-20210196665-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885
US-10940132-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885
US-11318111-B2 CCL5 inhibitors CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885
US-20220409566-A1 CCL5 Inhibitors CCL5, CCL11, CCR5 MAPT 4264/4885MTNR1A 3190/4885MTNR1B 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.